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Differences in mood instability 
in patients with bipolar disorder type I and II: 
a smartphone‑based study
Maria Faurholt‑Jepsen1* , Mads Frost2, Jonas Busk3, Ellen Margrethe Christensen1, Jakob E. Bardram3, 
Maj Vinberg1 and Lars Vedel Kessing1
Abstract 
Background: Mood instability in bipolar disorder is associated with a risk of relapse. This study investigated differ‑
ences in mood instability between patients with bipolar disorder type I and type II, which previously has been spar‑
ingly investigated.
Methods: Patients with bipolar disorder type I (n = 53) and type II (n = 31) used a daily smartphone‑based self‑moni‑
toring system for 9 months. Data in the present reflect 15.975 observations of daily collected smartphone‑based data 
on patient‑evaluated mood.
Results: In models adjusted for age, gender, illness duration and psychopharmacological treatment, patients with 
bipolar disorder type II experienced more mood instability during depression compared with patients with bipolar 
disorder type I (B: 0.27, 95% CI 0.007; 0.53, p = 0.044), but lower intensity of manic symptoms. Patients with bipolar disor‑
der type II did not experience lower mean mood or higher intensity of depressive symptoms compared with patients 
with bipolar disorder type I.
Conclusions: Compared to bipolar disorder type I, patients with bipolar disorder type II had higher mood instability 
for depression. Clinically it is of importance to identify these inter‑episodic symptoms. Future studies investigating the 
effect of treatment on mood instability measures are warranted.
Trial registration NCT02221336
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Background
Bipolar disorder is characterized by recurrent episodes 
of depression and (hypo)mania and in the form of sub-
syndromal mood swings. A substantial proportion of 
patients with bipolar disorder does not experience full 
remission, remains symptomatic during inter-episode 
periods and experience daily mood swings above what 
is experienced by healthy individuals (Bopp et al. 2010; 
Judd et  al. 2003; Joffe et  al. 2004). Mood instability 
between affective episodes is associated with sub-
stantial disability and poor prognostic factors such as 
increased risk of hospitalization, high risk of relapse, 
and impaired functioning (Bopp et al. 2010; Judd et al. 
2003; Joffe et  al. 2004; Kupka et  al. 2007; MacQueen 
et  al. 2003; Strejilevich et  al. 2013; Patel et  al. 2015). 
This emphasizes the serious nature of bipolar disorder. 
Noticing the clinically and functionally impact of mood 
instability, mood instability has been suggested as a 
target for treatment and may be a more sensitive out-
come measure in randomized controlled maintenance 
trials (RCT) than for example relapse or recurrence 
of affective episodes (Bopp et  al. 2010; Bonsall et  al. 
2012; Saunders et al. 2016). However, few studies have 
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suggested methods and measures on how to investigate 
mood instability and its possible predictors.
Patients with bipolar disorder type II seem to spend 
more time depressed, less time euthymic and experi-
ence greater depression instability than patients with 
bipolar disorder type I (Joffe et al. 2004; Faurholt-Jepsen 
et al. 2015a; O’Donnell et al. 2018; Vinberg et al. 2017). 
Previous studies investigating differences in mood 
between bipolar disorder type I and II have collected 
data on mood on a weekly and not daily basis and fur-
thermore used paper based charts, increasing the risk 
of recall bias and low compliance (Judd et al. 2003; Joffe 
et  al. 2004; Kupka et  al. 2007; MacQueen et  al. 2003; 
Strejilevich et al. 2013). One previous pilot study by the 
authors used smartphone-based daily electronic self-
monitoring of mood (Faurholt-Jepsen et  al. 2015a). In 
this study (the MONARCA I trial) including 33 patients 
with bipolar disorder, the patients with bipolar disor-
der type II spend less time euthymic, a higher propor-
tion of time with depressive symptoms and experienced 
higher mood instability for depression compared with 
patients with bipolar disorder type I (Faurholt-Jepsen 
et al. 2015a). Apart from this previous pilot study by the 
authors, no study has investigated differences in mood 
instability between patients with bipolar disorder type 
I and bipolar disorder type II using fine-grained daily 
electronic data. A recent paper discussed differences 
in momentary and retrospective trait self-report tech-
niques pointing out that retrospective self-monitoring 
is influenced by peak moments with greater salience of 
moments that occur closest in time to the assessment 
(Conner and Barrett 2012), which may be a particu-
lar problem when investigating mood instability given 
its dynamic structure in both polarity, variation and 
intensity. Ecological momentary assessments (EMA) 
reflect the methods used to collect assessments of indi-
vidual’s real-time states repeatedly over time and dur-
ing naturalistic settings, and may reduce recall bias 
(Shiffman et  al. 2008). Smartphones extends the use 
of EMA beyond its classical use for self-reports and 
offer the opportunity to collect fine-grained data unob-
trusively and outside the clinical settings (Ebner-Prie-
mer and Trull 2009), and enable collection of data on 
daily subsyndromal mood fluctuations. Based on daily 
smartphone-based self-monitoring data, the present 
report aimed to investigate, and replicate findings from 
the before mentioned study by the authors (Faurholt-
Jepsen et al. 2015a). We hypothesized that patients with 
bipolar disorder type II had lower mean mood level, 
spend less time euthymic, a higher proportion of time 
with depressive symptoms, experienced higher instabil-
ity for depression, i.e. more fluctuations in self-moni-
tored depressive mood, and experienced higher levels 
and intensity of depressive symptoms compared with 
patients with bipolar disorder type I.
Methods
Design, settings and participants
The patients were recruited as part of a randomized 
controlled single-blind parallel-group trial investigat-
ing the effect of smartphone-based self-monitoring, the 
MONARCA II trial (Faurholt-Jepsen et al. 2014) includ-
ing adult patients with bipolar disorder for a 9  months 
follow-up period. All patients with a diagnosis of bipolar 
disorder who previously had been treated at The Copen-
hagen Clinic for Affective Disorders, Denmark in the 
period 2004 to January 2016, currently treated at com-
munity psychiatric centers, private psychiatrists and gen-
eral practitioners were invited to participate in the trial, 
corresponding to approximately 735 potential partici-
pants. Treatment at the Copenhagen Clinic for Affective 
Disorders comprised combined psychopharmacological 
treatment as according to international guidelines, group 
based psychoeducation and supporting therapy for a 
total of 2-year (Kessing et al. 2013).
Inclusion criteria: Bipolar disorder diagnosis according 
to ICD-10 using the schedules for clinical assessments in 
neuropsychiatry (SCAN) (Wing et  al. 1990) and previ-
ously treatment at the Copenhagen Clinic for Affective 
Disorders. Exclusion criteria: schizophrenia, schizotypal 
or delusional disorders; previous use of the smartphone-
based monitoring system; pregnancy and lack of Danish 
language skills.
Patients were diagnostically categorized into bipolar 
disorder type I or II according to the SCAN interview. 
During the study the patients’ severity of depressive 
and manic were evaluated at baseline, after 4  weeks, 
3  months, 6  months and 9  months using the Hamilton 
Depression Rating Scale 17-items (HDRS) (Hamilton 
1967) and the Young Mania Rating Scale (YMRS) (Young 
et al. 1978).
Smartphone‑based monitoring
Patients were randomized to using a smartphone-based 
monitoring system (the MONARCA II system) for daily 
self-monitoring (intervention group) or treatment as 
usual (control group). Only patients included in the 
intervention group collecting daily smartphone-based 
self-monitoring data were included and presented in the 
present report.
Patients in the intervention group used a smartphone 
with the MONARCA II app installed and were instructed 
to use the system for daily evaluation for 9  months. 
The MONARCA II system allowed for evaluation of 
the following measures on a daily basis: mood (scored 
on a scale from − 3 to + 3); sleep duration (measured 
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in half-hour intervals); medicine intake; activity level 
(scored on a scale from − 3 to + 3); mixed mood (scored 
on a scale from 1 to 3); irritability (scored on a scale from 
1 to 3); anxiety (scored on a scale from 1 to 3); cognitive 
problems (scored on a scale from 1 to 3); alcohol con-
sumption; and stress (scored on a scale from 1 to 3). The 
patients were prompted to evaluate by an alarm set at a 
self-chosen time during the day. Further details regard-
ing the MONARCA II system are described elsewhere 
(Faurholt-Jepsen et al. 2014).
Statistical methods
The hypotheses and statistical analyses were defined á 
priori. The validity of self-monitored mood compared 
with clinically rated depressive and manic reflected by 
the HDRS and the YMRS, respectively was investigated. 
Since the HDRS and the YMRS reflects clinically rated 
severity of depressive and manic symptoms for the past 
4  days, the mean self-monitored mood for the days the 
scales were reflecting were used in the analyses of the 
validity of self-monitored mood. A two-level linear mixed 
effect model, which accommodates both variation of the 
variables of interest within patients (intra-individual vari-
ation) and between individuals (inter-individuals varia-
tion) was employed. The models including a fixed effect 
of visit number (baseline, 4 weeks, 3 months, 6 months, 
9 months) and a patients-specific random effect allowing 
for individual intercept and a slope for each participant 
were employed. Level one represented repeated meas-
ures of clinically rated symptoms (HDRS and YMRS) and 
level two represented inter-individual variation.
Differences in mean sleep duration, mood level and 
proportion of time with mixed symptoms were investi-
gated by means of analysis of covariance (ANCOVA). To 
summarize the patient profiles over time summary meas-
ures or indexes covering three areas (instability, symptom 
load and intensity) as indicators of illness activity were 
calculated for each patient in the same way as in our pre-
vious paper based on daily self-monitored data on mood 
scores (Faurholt-Jepsen et al. 2015a) and as suggested and 
used by others (Strejilevich et al. 2013) (data presented in 
Table 2):
1. Mood instability factors: A mood instability fac-
tor measure was calculated as the number of mood 
changes divided by the number of weeks followed. A 
mood instability factor for depression was calculated 
as the number of mood changes of depressive polar-
ity divided by the number of weeks followed. A mood 
instability factor for mania was calculated as the 
number of mood changes of manic polarity divided 
be the number of weeks followed.
2. Mood symptomatic factors: A mood symptomatic 
factor for depression was calculated as the number 
of days with depressive symptoms < − 0.5 on a mood 
scale from − 3 to + 3 divided by the number of weeks 
followed. A mood symptomatic factor for mania was 
calculated as the number of days with manic symp-
toms > + 0.5 on a mood scale from − 3 to + 3 divided 
by the number of weeks followed.
3. Mood intensity: A mood intensity factor for depres-
sion was calculated as the summary score of depres-
sive symptoms divided by the number of weeks 
followed. A mood intensity factor for mania was cal-
culated as the summary score of manic symptoms 
divided by the number of weeks followed.
In addition to these measures and as suggested by oth-
ers, mood instability scores reflecting the extent to which 
consecutively measured mood differ from one another 
during the follow-up period were computed for each user 
by applying the root mean square successive difference 
(rMSSD) method, taking the square root of the sum of 
the squared differences between daily and previous day 
mood scores (O’Donnell et  al. 2018; Ebner-Priemer and 
Trull 2009). The rMSSD reflects both size and temporal 
order of changes in mood. Higher rMSSD scores indicate 
more instability. Previous reports have demonstrated the 
construct validity of this method (Ebner-Priemer and 
Trull 2009; Jahng et al. 2008).
Regression analyses were used to evaluate the rela-
tionship between the different calculated mood indexes 
and bipolar disorder type I or bipolar disorder type II, 
respectively. First, we considered an unadjusted model 
(model 1). Secondly, we considered a model adjusted 
for age and gender (model 2). Thirdly, we considered a 
model adjusted for age, gender, illness duration and psy-
chopharmacological treatment (anticonvulsant treatment 
yes/no, antipsychotic treatment yes/no, antidepressant 
treatment yes/no, lithium treatment yes/no) (model 3) as 
these variables could affect the differences in mood insta-
bility measures between the two groups. Model assump-
tions were checked for each of the statistical analyses. As 
few prior studies have investigated differences in mood 
instability indexes between bipolar disorder type I and II 
we were not able to make statistical power analyses prior 
to the study since potential effects were unknown. The 
overall hypotheses were made a priori based on our prior 
findings within patients with bipolar disorder. Neverthe-
less, as these hypotheses included several measures on 
mood instability, the present study should be considered 
as hypotheses generating and the results needs further 
replication. Consequently, we did not account for multi-
ple testing in the statistical models. p-values below 0.05 
were considered statistical significant. Data were entered 
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using Excel and  Epidata®, STATA (StataCorp LP, Collega 
Station, TX, USA) version 12.1 was used for statistical 
analyses.
Ethical considerations
Ethical permission was obtained from the Regional Eth-
ics Committee in The Capital Region of Denmark and 
The Danish Data Protection Agency (H-2-2014-059).
Results
Background characteristics
From October 2014 to January 2018, a total of 85 patients 
collected daily smartphone-based self-monitoring data 
(the intervention group of the MONARCA II trial) for 
a study period of 9 months. In total 84 patient provided 
self-monitoring data during the study and were included 
in the present study (bipolar disorder type I n = 53, bipo-
lar disorder type II n = 31). As presented in Table  1, 
patients had a mean age of 43.0  years (SD 12.3) and 51 
(61.2%) were of female gender. Patients with bipolar dis-
order type I were more often in prescribed treatment 
with antipsychotics compared with patients with bipolar 
disorder type II (bipolar disorder type I: 59.3%; bipolar 
disorder type II: 32.3%) (Table 1).
At baseline a total of 52.9% (n = 44) of the patients had 
a HDRS score ≤ 7 and 87.1% (n = 73) had a HDRS score 
≤ 14. A total of 85.3% (n = 72) had a YMRS score ≤ 7 and 
97.6% (n = 82) had a YMRS score ≤ 14. During the entire 
9 months follow-up period 85.6% (n = 72) of the patients 
had a HDRS score ≤ 14 and 97.5% (n = 82) had a YMRS 
score ≤ 14. During the study patients adhered to self-
monitoring with a mean of 72.6% (a mean of 190 days) of 
the days. Data in the present report are based on 15.975 
daily smartphone-based self-monitored observations.
Regarding the validity of self-monitored mood com-
pared with clinically rated depressive and manic symp-
toms, there was a statistically significant negative 
association between self-monitored mood and scores 
on the HDRS in both unadjusted models and in mod-
els adjusted for age, gender and psychopharmacological 
treatment (adjusted model B: − 0.033, 95% CI − 0.046; 
− 0.20, p < 0.0001). Thus, for every increase of 10 points 
on the HDRS there was a decrease of 0.33 point on the 
self-monitoring mood scale (range − 3 to + 3). Also, there 
was a statistically significant positive association between 
self-monitored mood and scores on the YMRS in both 
unadjusted models and in models adjusted for age, gen-
der and psychopharmacological treatment (adjusted 
model B: 0.044, 95% CI 0.023; 0.066, p < 0.0001). Thus, 
for every increase of 10 points on the YMRS there was an 
increase of 0.44 point on the self-monitoring mood scale 
(range − 3 to + 3). Analyses including BD type (BD type I 
or II) did not alter the estimates.
Bipolar disorder subtype and self‑monitored smartphone 
data
Overall, regardless the bipolar subtype, the patients had a 
mean mood level below zero and reported mixed symp-
toms a large proportion of time when experiencing levels 
of depression or mania during the study, but there were 
no statistically significant differences (all p-values > 0.05) 
between patients with bipolar disorder type I and bipolar 
disorder type II in the self-monitored mean mood level 
[patients with bipolar disorder type I: − 0.15 (95% CI 
− 0.26; − 0.043) vs. patients with bipolar disorder type II: 
Table 1 Background characteristics of patients with bipolar disorder I and II, N = 84
Data are mean (SD), median [IQR] or proportions (n) unless otherwise stated
All patients (n = 84) Bipolar disorder type I 
(n = 53)
Bipolar disorder type II 
(n = 31)
p
Age (years) 43.0 (12.3) 42.8 (11.9) 43.4 (13.3) 0.85
Female gender, % (n) 61.2 (51) 64.8 (34) 54.8 (17) 0.36
Full time employment, % (n) 17.7 (15) 16.7 (9) 19.4 (6) 0.73
Illness duration (years) 18.0 (10.1) 17.7 (10.6) 18.6 (9.5) 0.71
Number of previous depressive episodes 4 [2–10] 3.5 [2–9] 5 [3–10] 0.21
Number of previous (hypo)manic episodes 3 [2–7] 3 [2–6] 5 [2–8] 0.33
Hamilton depression rating scale score, baseline 7.6 (5.0) 7.9 (5.0) 7.2 (6.0) 0.57
Young Mania Rating Scale score, baseline 3.2 (4.6) 4.1 (5.6) 2.6 (3.0) 0.16
Psychopharmacological treatment
 Anticonvulsants, % (n) 55.9 (47) 57.4 (30) 54.8 (17) 0.82
 Antipsychotics, % (n) 48.8 (41) 59.3 (31) 32.3 (10) 0.017
 Antidepressants, % (n) 22.6 (19) 26.4 (14) 16.1 (5) 0.28
 Lithium, % (n) 63.1 (53) 68.5 (36) 54.8 (17) 0.21
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− 0.20 (95% CI − 0.33; − 0.065)], the proportion of over-
all time with mixed symptoms [patients with bipolar dis-
order type I: 8.77% (95% CI 4.75; 15.63) vs. patients with 
bipolar disorder type II: 3.51% (95% CI 0.86; 13.23)], the 
proportion of time with mixed symptoms when scoring 
< − 0.5 on a mood scale [patients with bipolar disorder 
type I: 16.67% (95% CI 8.07; 41.40) vs. patients with bipo-
lar disorder type II: 11.11% (95% CI 1.45; 37.73)] and the 
proportion of time with mixed symptoms when scoring 
> + 0.5 om a mood scale [patients with bipolar disorder 
type I: 25.00% (95% CI 4.56; 54.56) vs. patients with bipo-
lar disorder type II: 16.66% (95% CI 5.95; 26.18)].
Patients with bipolar disorder type II had a statistically 
significantly lower mean sleep duration per night (hours) 
compared with patients with bipolar disorder type I 
(6.54 (95% CI 6.18; 6.90) vs. 7.27 (95% CI 6.98; 7.57) vs., 
p = 0.036).
Bipolar disorder subtype and mood instability
Unadjusted and adjusted regression models on indexes 
reflecting mood instability measures are presented in 
Table 2. As hypothesized, patients with bipolar disorder 
type II had statically significantly higher mood instabil-
ity factor for depression (models adjusted for age, gender, 
illness duration and psychopharmacological treatment 
(anticonvulsant treatment yes/no, antipsychotic treat-
ment yes/no, antidepressant treatment yes/no, lithium 
treatment yes/no): B: 0.11, 95% CI 0.0085; 0.21, p = 0.034) 
compared with patient with bipolar disorder type I.
There was no significant correlation between mood 
instability factor for depression and self-monitored sleep 
duration (B: − 0.01, 95% CI − 0.040; 0.02, p = 0.44). Fur-
thermore, patients with bipolar disorder type II had sta-
tistically significantly lower Mood symptomatic factor for 
mania and mood intensity factor for mania (mood inten-
sity factor for mania: models adjusted for age, gender, 
illness duration and psychopharmacological treatment 
(anticonvulsant treatment yes/no, antipsychotic treat-
ment yes/no, antidepressant treatment yes/no, lithium 
treatment yes/no): B: − 0.074, 95% CI − 0.15; − 0.0022, 
p = 0.043) compared with patients with bipolar disorder 
type I. There were no differences in mood instability fac-
tor, mood instability factor for mania, mood symptomatic 
factor for depression, mood intensity factor depression 
and mood instability score between patients with bipolar 
disorder type I and bipolar disorder type II.
Discussion
Apart from one previous study by the authors (Faurholt-
Jepsen et al. 2015a), this is the first study investigating dif-
ferences in daily smartphone-based self-monitored data 
collected over 9  months on illness activity in patients 
with bipolar disorder type I and bipolar disorder type 
II. As hypothesized we found that patients with bipo-
lar disorder type II experienced higher mood instability 
for depression compared with patients with bipolar dis-
order type I, but lower intensity of manic symptoms. In 
addition, we found that in the entire sample regardless 
the bipolar disorder subtype, the patients had a mean 
mood level below zero during the 9-month study period 
and reported mixed symptoms a large proportion of 
time when experiencing levels of depression or mania. 
Table 2 Differences in mood instability indexes reflecting self-monitored illness activity in patients with bipolar disorder 
type I and type II using smartphones (bipolar disorder type I serve as reference), N = 84
Italic values indicate statistical significance level (p value)
A: MIF = number of mood changes/number of weeks followed; B: MIFD = number of mood changes of depressive polarity/number of weeks followed; C: 
MIFM = number of mood changes of manic polarity/number of weeks followed; D: MSFD = number of days with depressive symptoms < − 0.5 on a mood scale from 
− 3 to + 3/number of weeks followed; E: MSFM = number of days with manic symptoms > 0.5 on a mood scale from − 3 to + 3/number of weeks followed; F: MIntFD: 
the summaric score of depressive symptoms/number of weeks followed; G: MintFM: the summaric score of manic symptoms/number of weeks followed; H: MIS: scores 
were computed for each user by applying the root mean square successive difference (rMSSD) method, taking the square root of the sum of the squared differences 
between daily and previous day mood scores
a Model 1: unadjusted. Model 2: adjusted for age and gender. Model 3: adjusted for age, gender, illness duration and psychopharmacological treatment 
(anticonvulsant treatment yes/no, antipsychotics treatment yes/no, antidepressant treatment yes/no, lithium treatment yes/no)
Model  1a Model  2a Model  3a
B 95% CI p B 95% CI p B 95% CI p
A: Mood instability factor (MIF) − 0.19 − 0.50; 0.025 0.51 − 0.25 − 0.81; 0.32 0.38 − 0.33 − 0.91; 0.26 0.27
B: Mood instability factor for depression (MIFD) 0.24 − 0.025; 0.50 0.076 0.25 0.011; 0.51 0.061 0.27 0.007; 0.53 0.044
C: Mood instability factor for mania (MIFM) − 0.11 − 0.46; 0.24 0.53 − 0.15 − 0.50; 0.20 0.40 − 0.20 − 0.60; 0.20 0.32
D: Mood symptomatic factor for depression (MSFD) 0.30 − 0.37; 0.98 0.37 0.26 − 0.39; 0.92 0.43 0.26 − 0.39; 0.92 0.26
E: Mood symptomatic factor for mania (MSFM) − 0.24 − 0.49; 0.025 0.076 − 0.24 − 0.52; 0.029 0.080 − 0.33 − 0.64; − 0.021 0.037
F: Mood intensity factor for depression (MIntFD) 0.36 − 0.72; 1.43 0.51 0.29 0.75; 1.34 0.58 0.29 0.75; 1.34 0.58
G: Mood intensity factor for mania (MIntFM) − 0.24 0.50; 0.025 0.076 − 0.24 − 0.50; 0.023 0.073 − 0.29 − 0.56; − 0.10 0.042
H: Mood instability score (MIS) 0.037 − 0.53; 0.61 0.90 − 0.064 − 0.66; 0.53 0.83 − 0.064 − 0.66; 0.53 0.83
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Regardless the bipolar subtype, the patients were able 
to validly evaluate their level of depressive and manic 
symptoms.
The finding that patients with bipolar disorder type II 
experienced more instability for depressive symptoms 
compared with patients with bipolar disorder type I is 
in line with findings from other studies including a study 
from our group suggesting that bipolar disorder type 
II is not simply a less serious subtype of bipolar disor-
der (Bopp et  al. 2010; Judd et  al. 2003; Joffe et  al. 2004; 
Kupka et  al. 2007; Vinberg et  al. 2017). During the last 
decades there has been an increased shift from a focus 
on awareness of the impact of inter-episodic mood insta-
bility (MacQueen et  al. 2003; Harrison et  al. 2016), and 
a substantial proportion of patients with bipolar disorder 
experience subsyndromal mood swings on a daily basis 
even though they overall seem to be in remission. Mood 
instability is associated with poor prognostic factors 
including impaired functioning, increased risk of hospi-
talization, high risk of relapse, and comorbid substance 
use disorder (Bopp et al. 2010; Judd et al. 2003; Joffe et al. 
2004; Kupka et  al. 2007; Strejilevich et  al. 2013; Patel 
et al. 2015; O’Donnell et al. 2018; Gershon and Eidelman 
2015). The patients in the present study had a mean ill-
ness duration of 18.0  years (SD 10.1) and several prior 
depressive and manic episodes. Studies investigating 
whether differences in mood instability between bipolar 
disorder type I and bipolar disorder type II are intrinsic 
to bipolar disorder or a consequence of illness progres-
sion have not been conducted. However, illness duration 
was included as a possible confounder in the statisti-
cal analyses in the present study and did not alter the 
estimates. Smartphone-based monitoring of mood and 
mood instability in high-risk groups such as the adoles-
cent and emerging adult offspring of parents with bipolar 
disorder may be a fruitful new direction of early identifi-
cation and characterization of the prospective course of 
mood instability (Duffy et al. 2018; Kessing et al. 2017).
Mood instability may predict worse long-term clini-
cal course and functioning beyond what is predicted by 
prior and current depressive and/or (hypo)manic epi-
sodes (Strejilevich et al. 2013; McKnight et al. 2017) sup-
porting the idea that different measures of subsyndromal 
illness activity may be a more sensitive outcome meas-
ure in maintenance RCTs than for example time to first 
relapse or recurrence of affective episodes (Bopp et  al. 
2010; Bonsall et  al. 2012; Saunders et  al. 2016; Broome 
et al. 2015). Thus, there is a need to identify and monitor 
inter-episodic symptoms giving the opportunity to inter-
vene. Innovative RCT’s investigating the effect of treat-
ment interventions on mood instability are ongoing and 
will hopefully provide more insight to this area (Saunders 
et al. 2016).
Throughout the present study period all patients had 
continuous contact to a study nurse through a bi-direc-
tional feedback loop based on changes in the smart-
phone-based self-monitored data incorporated in the 
MONARCA II system (Faurholt-Jepsen et  al. 2014). 
However, despite this rather intensive intervention they 
presented with subsyndromal levels of symptoms dur-
ing large proportions of time, reflecting the serious and 
chronic nature of bipolar disorder.
In contrast to our hypotheses and in contrast to find-
ings from our previous study patients with bipolar disor-
der type II had a lower mean mood level or experienced 
higher levels and intensity of depressive symptoms com-
pared with patient with bipolar disorder type I (Faurholt-
Jepsen et al. 2015a). The findings on mood instability for 
depression and mood symptomatic factor for mania from 
the present study are in line with findings from our pre-
vious study. However, in contrast to our previous study, 
the present patients with bipolar disorder type II did not 
experience higher mood symptomatic factor for depres-
sion and mood intensity factor for depression factor. Dif-
ferences in findings between the two studies may be due 
to differences in the included samples in the two studies. 
Patients in our previous study were recruited early during 
their course of treatment, whereas patients in the present 
report had received two full years of outpatient treatment 
comprising combined evidence-based psychopharma-
cological treatment and supporting therapy, including 
psychoeducation at the specialized outpatient clinic. In 
our previous study a total of 27.2% of the patients were 
prescribed with antidepressants and 57.6% were pre-
scribed with lithium, whereas in the present study a total 
of 22.6% were prescribed with antidepressants and 63.1% 
were prescribed with lithium. In addition, a larger pro-
portion of the patients in the present study were in full 
time employment compared with the patients from the 
previous study (17.7% vs. 8.6%).
Limitations
Some limitations to the present report should be men-
tioned. First, the patients included in the study were 
recruited as part of a larger RCT and thus not recruited 
according the bipolar disorder subtype. The unequal 
group size between the two disorders was therefore not 
intended. The statistical power for the study was calcu-
lated for the original RCT and consequently power cal-
culations were not conducted for the present report 
(Faurholt-Jepsen et  al. 2015a). We did not correct for 
multiple testing since the study is considered as hypoth-
eses generating and the results needs further replication. 
However, it should be noted that if Bonferroni correc-
tions were applied none of the models would be statis-
tically significant. Second, regarding the generalizability 
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of the results, the patients included in the present study 
had previously been treated at The Copenhagen Clinic 
for Affective Disorders, Denmark which is a specialized 
outpatient clinic in the period 2004 to January 2016. 
Along this line, it cannot be excluded that the patients 
who agree to participate in the present study may repre-
sent a subgroup of patients with bipolar disorder. Third, 
the patients presented with rather low levels of depres-
sive and manic symptoms, and received different types, 
doses and combinations of psychopharmacological 
treatment during the study. Since a higher proportion 
of patients with bipolar disorder type I received antip-
sychotics compared with patients with bipolar disorder 
type II, the statistical analyses included the different psy-
chopharmacological treatments prescribed (anticonvul-
sant treatment yes/no, antipsychotic treatment yes/no, 
antidepressant treatment yes/no, lithium treatment yes/
no) as covariates. However, residual confounding due to 
differences in psychopharmacological treatment between 
the two groups cannot be excluded. It is likely that differ-
ences in psychopharmacological treatment (antipsychot-
ics) may affect differences in mood instability and should 
be investigated further in larger studies. Fourth, to date 
there are no clear consensus on the definition, measure-
ment, use and reporting of mood instability in patients 
with bipolar disorder, and thus the measures used in the 
present report were a combination of measures used 
by others and measures used by the authors in a previ-
ous study (Strejilevich et  al. 2013; Faurholt-Jepsen et  al. 
2015a; O’Donnell et  al. 2018; Ebner-Priemer and Trull 
2009). Using, defining, measuring and reporting mood 
instability in a standardized way across studies could 
improve the quality, reproducibility and comparison of 
results between studies. Fifth, we did not use last-obser-
vation-carried-forward method or imputation techniques 
to handle missing data since there was a high adherence 
to self-monitoring during the study. The patients pre-
sented with rather low level of depressive and manic 
symptoms and therefore data is estimated to be missing 
at random. It cannot be excluded that patients did not 
conduct the self-monitoring during the most severe time 
point. However, the patients were able to validly evalu-
ated their level of depressive and manic symptoms. Inves-
tigating the validity of self-monitored symptoms during 
more severe affective episodes could be a target for future 
studies.
Sixth, it may be that systematic self-monitoring and 
reporting of mood could potentially in itself affect mood 
and mood awareness. Along this line, the risk of patients 
using the smartphone-based self-monitoring system sys-
tematically reported lower mood, to gain attention from 
the study nurse leading to non-random measurement 
error, must be considered. However, our previous studies 
using the same smartphone-based self-monitoring sys-
tem have showed neither positive nor negative effects 
of smartphone-based self-monitoring, and that the self-
monitored mood levels correlated statistically significant 
with clinically rated depressive and manic symptoms 
measured using the Hamilton Depression Rating Scale 
and the Young Mania Rating Scale (Faurholt-Jepsen et al. 
2015b, 2015c).
Perspectives
Smartphones are ubiquitous and reflect an unobtrusive 
way of collecting fine-grained real-time data during natu-
ralistic settings on the course of illness and detailed char-
acterization of prodromal and subsyndromal symptoms 
of depression and (hypo)mania in patients with bipolar 
disorder. Measures of mood instability may be a prom-
ising measure of inter-episodic illness activity in bipolar 
disorder and may be a more sensitive outcome meas-
ure in maintenance RCTs than for example time to first 
relapse or recurrence of affective episodes since patients 
continue to experience subsyndromal mood swings.
Conclusions
Patients with bipolar disorder type II experienced higher 
mood instability for depression compared with patients 
with bipolar disorder type I. Patients with bipolar disor-
der type I and II experienced mixed symptoms a large 
proportion of time. These findings emphasize the need to 
monitor, identify and treat subsyndromal inter-episodic 
symptoms. Future studies investigating the effect of treat-
ment on mood instability measures are needed.
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